172@29@17@107!~!172@29@0@53!~!|news|business|medicine-sales-decline-in-august-after-two-months-report-5810361.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Subscribe to Moneycontrol Pro and get 365 bonus InterMiles! Use Code: INTERMILES
you are here: HomeNewsBusiness
Last Updated : Sep 08, 2020 09:03 AM IST | Source: Moneycontrol.com

Medicine sales decline in August after two months: Report

While sales of cardiac and anti-diabetic drugs, vitamins rose in August, anti-infective and respiratory drugs saw a decline in volumes

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Sales of medicines in India saw a slump in August after two months, with overall sales falling over 2.2 percent year-on-year (YoY) to Rs 12,162 crore.

Total medicine sales increased by 2.4 percent and 0.2 percent in June and July respectively, Mint reported citing data from market research firm AIOCD-AWACS.

While sales of cardiac and anti-diabetic drugs, vitamins rose in August, anti-infective and respiratory drugs saw a decline in volumes, the report said.

Close

Moneycontrol could not independently verify the story.

Sales of anti-infectives fell 11 percent YoY in August, declining for the fifth consecutive month, Mint reported.

This could be because patients are avoiding going to doctors’ clinics and hospital out-patient departments due to fears of contracting COVID-19, the report said. It could also indicate that the number of infections has lowered since people have been staying at home.

Sales of cardiac and anti-diabetic medicines grew 11.5 percent and 1.6 percent respectively in August, the report said.

While sales of vitamins grew 6.2 percent in August, respiratory drugs declined 12.4 percent, as against a 2 percent drop during the previous month.

All top 10 drugmakers in India, barring Cipla and Macleods Pharmaceuticals, recorded a 1.1-7-7 percent fall in sales.

Cipla, which manufactures COVID-19 drugs such as favipiravir, remdesivir and tocilizumab, posted a 7.4 percent growth in overall sales during August, the report said.

Other companies that manufacture COVID-19 medicines, such as Glenmark Pharmaceuticals and Ipca Laboratories, also reported a growth in sales.

Glenmark Pharmaceuticals saw a one-third spike in sales at Rs 347 crore during August, Ipca Laboratories saw a 9.8 percent increase in volumes at Rs 200 crore.

First Published on Sep 8, 2020 09:03 am
Sections